MedTrace Logo

HyQvia in Multifocal Motor Neuropathy

NCT02885259 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2016-08-31

No results posted yet for this study

Summary

Subcutaneous immunoglobulin (SCIG) and recombinant human hyaluronidase (rHuPH20) will be tested in patient witch MMN and currently under maintenance treatment with IVIG for safety, tolerability and efficacy.

Conditions

  • Multifocal Motor Neuropathy

Interventions

DRUG

rHuPH20

human immunoglobulin and one vial of recombinant human hyaluronidase

Sponsors & Collaborators

  • UMC Utrecht

    lead OTHER

Principal Investigators

  • Leonard van den Berg, prof · UMCU

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-09-30
Primary Completion
2017-12-31
Completion
2018-01-31

Countries

  • Netherlands

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02885259 on ClinicalTrials.gov